SecBot SecBot

HAFC

HANMI FINANCIAL CORP
Nasdaq· National Commercial Banks· Inc. DE· CIK 0001109242 Traditional Finance
$32.41 +0.24 (+0.75%)
Oct 27 4:00 PM ET · prev $32.17
Market cap
$953.2M
Small cap
Median target
$34.00
+5% · range $33.00–36.00
1 year
+18.6%
from $27.32 · Oct 28
30 days
+2.6%
from $31.60
52-week range
$24.77–33.31
−3% from high · low Jan 28
Avg volume 20D
198.2K
shares / day
Short interest
1.23M
≈4.2% of shares · −4.9%
Days to cover
6.1
at average volume
Insider net
−$265.6K
0 buyers · 2 sellers · since Mar 10
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
16
analyzed by SecBot
SecBot read MIXED 5 reports · 90 days
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 2/5
Strongest NEUTRAL Hanmi Financial Corporation furnished an investor slide presentation for a non-deal roadshow on August…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $265.6K.

  • InstitutionsMIXED

    Q2 2026: 22 added (0 new), 15 trimmed or exited.

  • Short sellersSTEADY

    Short interest −4.9% to 1.23M shares. 6.1 days to cover, ≈4.2% of shares.

  • TrendRANGE

    3% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdADD371,130$12.0M
PRICE T ROWE ASSOCIATES INC /MD/ADD312,194$10.1M
Nuveen, LLCDOUBLED279,125$9.0M
CITADEL ADVISORS LLCADD169,213$5.5M
Trexquant Investment LPADD167,026$5.4M
Point72 Asset Management, L.P.ADD120,240$3.9M
RENAISSANCE TECHNOLOGIES LLCTRIM117,358$3.8M
UBS Group AGTRIM107,622$3.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jul 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +5%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Jul 23, 2026DA Davidson
MAINTAIN
MAINTAINNeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$265.6K
sold · 2 insiders
DateInsiderTypeValue
Jun 8, 2026
Kim Anthony I.
Chief Banking Officer
SELL$163.9K
May 27, 2026
Ball Christine P
Director
AWARD2,298 sh
May 27, 2026
Medici Daniel John
Director
AWARD2,298 sh
May 27, 2026
Williams Thomas James
Director
AWARD2,298 sh
May 27, 2026
Lee Gloria J
Director
AWARD2,298 sh
May 27, 2026
Rosenblum David L
Director
AWARD2,298 sh
May 27, 2026
Marasco James A
Director
AWARD2,298 sh
May 27, 2026
Ahn John J
Director
AWARD2,298 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY$3.19$3.16–$3.21+0.2%$296.3M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
1,231,146
shares short
-4.9%
vs prior settlement
6.1
days to cover
≈4.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 27, 2026 Earnings
🔒 Fresh data, subscribers only
Oct 13, 2026 SEC
Hanmi Bank announced it will host a conference call to discuss its Q3 2026 results.
PRESS-RELEASE — Impact 1/10
Jun 30, 2026 Inst.
Qube Research & Technologies — ADD
371,130 shares ($12.0M)
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES — ADD
312,194 shares ($10.1M)
Jun 8, 2026 Insider
Kim Anthony I. sold 5,333 shares
Chief Banking Officer @ $30.73 ($163.9K)
May 27, 2026 Insider
Ball Christine P was granted 2,298 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Earnings
🔒 Fresh data, subscribers only
Oct 27, 2026
Earnings result
HAFC Q3 2026 Earnings: EPS $0.8 (-3.0% vs est)
Oct 25, 2026
Trial readout
T-90d Trial Readout: HM15275 (Phase 2)
Trial: Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus Sponsor: Hanmi Pharmaceutical Company Limited Phase…
Oct 18, 2026
Trial readout
T-90d Trial Readout: HM15275 (Phase 2)
Trial: Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus Sponsor: Hanmi Pharmaceutical Company Limited Phase…
Oct 13, 2026
Earnings
Hanmi Financial Corporation Announces Third Quarter 2026 Earnings and Conference Call Date
LOS ANGELES, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Hanmi Financial Corporation (Nasdaq: HAFC) (“Hanmi”), the holding company for Hanmi Bank, today…

SecBot reports

16 filings · 2 bullish · 0 bearish · 14 neutral
All HAFC filing & press-release reports (16)